Institute Financials
| MRES Stock | USD 0.01 0 13.97% |
Institute |
Please note, the imprecision that can be found in Institute's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Institute of Biomedical. Check Institute's Beneish M Score to see the likelihood of Institute's management manipulating its earnings.
Institute Stock Summary
Institute competes with Sino Biopharmaceutica, Defence Therapeutics, Enlivex Therapeutics, Achilles Therapeutics, and NextCure. Institute of Biomedical Research Corp. provides biomedical research and analytical services in Montenegro and internationally. Institute of Biomedical Research Corp. was founded in 2010 and is based in Podgorica, Montenegro with a representative office in Montreal, Canada. Institute is traded on OTC Exchange in the United States.| Instrument | USA Pink Sheet View All |
| Exchange | PINK Exchange |
| Business Address | Ljubljanska bb, Podgorica, |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | mrescorp.com |
| Phone | 382 20 663 075 |
| Currency | USD - US Dollar |
Institute Key Financial Ratios
There are many critical financial ratios that Institute's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Institute of Biomedical reports annually and quarterly.| Beta | 1.71 | |||
| Z Score | -14.0 |
Institute Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Institute's current stock value. Our valuation model uses many indicators to compare Institute value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Institute competition to find correlations between indicators driving Institute's intrinsic value. More Info.Institute of Biomedical is rated below average in current valuation category among its peers. It is regarded second in shares outstanding category among its peers creating about 333.33 of Shares Outstanding per Current Valuation. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Institute's earnings, one of the primary drivers of an investment's value.Institute of Biomedical Systematic Risk
Institute's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Institute volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Institute of Biomedical correlated with the market. If Beta is less than 0 Institute generally moves in the opposite direction as compared to the market. If Institute Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Institute of Biomedical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Institute is generally in the same direction as the market. If Beta > 1 Institute moves generally in the same direction as, but more than the movement of the benchmark.
Institute March 23, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Institute help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Institute of Biomedical. We use our internally-developed statistical techniques to arrive at the intrinsic value of Institute of Biomedical based on widely used predictive technical indicators. In general, we focus on analyzing Institute Pink Sheet price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Institute's daily price indicators and compare them against related drivers.
| Downside Deviation | 8.79 | |||
| Information Ratio | 0.0557 | |||
| Maximum Drawdown | 67.81 | |||
| Value At Risk | (13.97) | |||
| Potential Upside | 19.79 |
Additional Tools for Institute Pink Sheet Analysis
When running Institute's price analysis, check to measure Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Institute is operating at the current time. Most of Institute's value examination focuses on studying past and present price action to predict the probability of Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Institute's price. Additionally, you may evaluate how the addition of Institute to your portfolios can decrease your overall portfolio volatility.